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Correction 
Amoxicillin for Fever and Sore Throat due to Non-exudative Pharyngotonsillitis: 
Beneficial or Harmful? 
In International Journal of Infectious Diseases, Volume 4, Number 2,2000, ‘Amoxicillin for Fever and Sore Throat 
due to Non-exudative Pharyngotonsillitis: Beneficial or Harmful?” page 73, some of the data in Table 3 was incorrectly 
placed. The corrected table appears below; please note these changes in your copy. 
Table 3. Duration of Fever and Sore Throat before and after Treatment, by Drug Group 
Variable 
Durations of Fever or Sore Throat (d) 
Mean 2 SD (Number of Cases) 
Amoxicillin Placebo 
95% C/ of Difference 







NA = not applicable. 
1.97 2 1.08 (584) 2.06 ‘-’ 1 .I 9 (584) NA 0.0670 
2.18 t 1.23 (591) 2.31 k 1.71 (588) NA 0.0870 
2.46 t 1.27 (431) 2.48 t 1.30 (436) -0.2, 0.1 0.7780 
3.01 2 1.84 (431) 3.04 2 1.86 (436) -0.3, 0.2 0.7990 
